Because the five muscarinic acetylcholine receptor subtypes have overlapping distributions in many CNS tissues, and because ligands with a high degree of selectivity for a given subtype long remained elusive, it has been difficult to determine the physiological functions of each receptor. Genetically engineered knockout mice, in which one or more muscarinic acetylcholine receptor subtype has been inactivated, have been instrumental in identifying muscarinic receptor functions in the CNS, at the neuronal, circuit, and behavioral level. These studies revealed important functions of muscarinic receptors modulating neuronal activity and neurotransmitter release in many brain regions, shaping neuronal plasticity, and affecting functions ranging from motor and sensory function to cognitive processes. As gene targeting technology evolves including the use of conditional, cell type specific strains, knockout mice are likely to continue to provide valuable insights into brain physiology and pathophysiology, and advance the development of new medications for a range of conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia, and addictions, as well as non-opioid analgesics.
Unlike its classic neurotransmitter function in the periphery (e.g., at neuromuscular junctions), in the CNS, acetylcholine often functions as a modulator of neuronal activity. Acetylcholine, released from projection neurons and/or local interneurons, increases or decreases neuronal excitability and synaptic release of neurotransmitters, and modulates temporal patterns and coordination of activity between neurons (see Goldberg et al., 2012; Picciotto et al., 2012; Smythies, 2005) . Given the complex and overlapping distribution of nicotinic and muscarinic acetylcholine receptor (mAChR) subtypes across the brain, combined with the difficulty in generating ligands with a high degree of selectivity at each muscarinic receptor subtype, transgenic mice lacking one or more functional mAChR subtypes (M 1 À/À to M 5 À/À mice) have been invaluable in dissecting these neuronal functions of acetylcholine (previously reviewed in Gautam et al., 2006; Matsui et al., 2004; Wess, 2012 Wess, , 2004 Wess et al., 2007) . Please see chapter 1 of the special issue, "Central muscarinic cholinergic system" for information about mAChR distribution and general characteristics.
Striatal functions
Acetylcholine in striatal tissues exemplifies cholinergic interneuron (CIN) function: representing only 1e2% of striatal neurons, the tonically active CINs are the major cholinergic input to the region and provide extensive innervation that potently modulate striatal functions (Gonzales and Smith, 2015) . Striatal CINs express G i -coupled M 2 and M 4 mAChRs (Bernard et al., 1992; Yan and Surmeier, 1996) and these are proposed to mediate suppression of dopamine transmission in the striatum (Bonsi et al., 2008; Shin et al., 2015; Zhang et al., 2002a) . Initial investigation of dopamine release in slices from mAChR knockout mice suggested that multiple mAChR subtypes are involved in regulation of striatal dopamine, with some receptors (M 3 and M 4 ) mediating their effects indirectly via modulations of striatal GABA tone (Zhang et al., 2002b) . While the effects of inactivation of different mAChR subtypes on dopamine release have been conflicting (Bendor et al., 2010; Forster et al., 2002; Foster et al., 2014b; Tzavara, 2004; Yamada et al., 2001; Zhang et al., 2002b) , studies applying fastscan cyclic voltammetry and amperometry have been valuable in the understanding of these, and conclude that a key action of mAChRs is to modulate acetylcholine tone from CINs (Shin et al., 2015; Threlfell et al., 2010) . Depression of striatal dopamine transmission is proposed to arise from a disynaptic mechanism by which activation of M 2 /M 4 autoreceptors on CINs creates an inhibitory outward current and decreased conductance, resulting in decreased cholinergic tone and subsequent nicotinic acetylcholine receptor-dependent dopamine transmission (Bonsi et al., 2008; Shin et al., 2015; Threlfell et al., 2010) . This modulation is not simply inhibitory, but also makes dopamine release more sensitive to the frequency of neuronal firing, and seems to be controlled by M 2 and M 4 mAChRs in the dorsal striatum, but only by M 4 mAChRs in the ventral striatum/nucleus accumbens (Threlfell et al., 2010; Threlfell and Cragg, 2011) . Consistent with this, whole-tissue striatal dopamine and metabolites were normal in M 4 À/À mice (Dencker et al., 2012b) , but M 4 À/À mice displayed increased psychostimulant-induced extracellular dopamine efflux in the nucleus accumbens Tzavara, 2004) . No alteration of accumbal psychostimulant-induced dopamine efflux was detected in M 2 À/À mice (Tzavara, 2004) , in agreement with the notion that M 4 , but not M 2 receptor activation exert inhibitory control on evoked dopamine release in ventral striatum. The dense and extensive axonal branching of CINs results in a widespread release of acetylcholine, which acts locally on cholinergic receptors on striatal output medium spiny neurons (MSN). Postsynaptically, excitability of MSN in response to excitatory and inhibitory inputs is modulated by M 1 receptor activation, via KCNQ potassium channel regulation and endocannabinoid-mediated signaling (Narushima et al., 2007; Shen, 2005) . Several lines of evidence including knockout studies indicate that M 1 receptor stimulation enhances the dendritic excitability and spiking of MSN, making them more "responsive" to corticostriatal input (Ding et al., 2010) . This modulation happens preferentially in the D 2 -expressing indirect pathway MSN, thought to provide the inhibitory, "nogo", side of striatal output (Ding et al., 2010) . Measured at the level of striatal tissue rather than at the cell level, M 1 À/À mice had significantly elevated extracellular dopamine levels despite normal whole-tissue levels (i.e., indicating increased release), and dopamine efflux in response to amphetamine was exacerbated (Gerber et al., 2001) . M 4 mAChRs are densely co-expressed with dopamine D 1 receptors on MSNs (Ince et al., 1997; Yan et al., 2001) , and were suggested to act as a functional antagonist of D 1 receptor-mediated cyclic AMP-dependent signaling pathways (Jeon et al., 2010; Onali and Olianas, 2002 ; see also section 3). M 4 receptors on MSN were also shown to mediate prolonged suppression of dopamine release, through a cannabinoid CB 2 receptor dependent mechanism (Foster et al., 2016) . Corticostriatal glutamatergic transmission is depressed by stimulation of presynaptic M 4 mAChRs (Higley et al., 2009; Pakhotin and Bracci, 2007; Pancani et al., 2014) . Finally, a specific Ca 2þ /calmodulin-dependent protein kinase IIa (CAMKIIa) has been found to bind directly and selectively to the M 4 receptor upon calcium influx and to mediate potentiation of M 4 receptor signaling (Guo et al., 2010a (Guo et al., , 2010b . Thus, overall, activation of striatal M 1 and M 4 receptors modulates dopaminergic signaling towards inhibition. Striatal tissues receive dopaminergic projections from the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNc), in which only the M 5 mAChR subtype has been detected. Stimulation of those M 5 receptors increases neuronal activity and dopamine release, and is necessary for sustained striatal dopamine release (Forster et al., 2002; Foster et al., 2014b) . Dopaminergic VTA and SNc neurons in turn receive input from cholinergic neurons in the laterodorsal pontine tegmental nuclei, which are modulated by inhibitory M 2 and M 4 receptors (Kohlmeier et al., 2012) . In M 5 À/À mice, extracellular nucleus accumbens dopamine levels were comparable to wild-type controls at baseline, after depolarization (K þ )-induced release, and after electrical stimulation of the medial forebrain bundle Schmidt et al., 2010) . However, M 5 À/À mice showed dramatically reduced dopamine efflux after stimulation of the laterodorsal or pedunculopontine tegmental nuclei, and electrically evoked dopamine release in striatal slices from M 5 À/À mice was moderately decreased (Bendor et al., 2010; Forster et al., 2002; Steidl et al., 2011) . Morphine-induced increases in striatal dopamine levels were also blunted in M 5 À/À mice Steidl et al., 2011) . M 5 mAChRs are expressed by the dopaminergic neurons within the VTA and SNc, but have not been detected on axons, in the striatum (Vilaro et al., 1990; Weiner et al., 1990) . Nevertheless, recent studies suggest that M 5 receptors within the striatum may also modulate dopamine release, but findings varied in different experimental approaches, and generally suggested a relatively minor contribution of M 5 receptors relative to other mechanism (Bendor et al., 2010; Foster et al., 2014b; Shin et al., 2015) . Recycling of the M 5 mAChRs at dopaminergic terminals has been proposed to be highly important for maintaining function. Bendor et al. (2010) report of a new receptor cycling pathway where interaction of the GTPase activating protein AGAP1 in combination adaptor protein AP-3 is required for endocytic recycling of the M 5 receptor. These effects of M 5 receptor inactivation on dopamine release has led to an interest in the receptor with regard to addiction (see 2.5).
Hippocampal functions
In the hippocampus, synaptically released acetylcholine facilitates learning and memory through cholinergic induction of neural oscillations. Excitatory hippocampal pathways comprised of CA3 and CA1 pyramidal neurons are modulated by mAChRs. Studies using mAChR knockout lines suggest that M 1 and M 4 receptors (and not M 2 /M 3 /M 5 ) are the major mAChR subtypes responsible for cholinergic modulation of the excitatory hippocampal circuits (Dasari and Gulledge, 2011; Dennis et al., 2016; Kremin et al., 2006) . Whole cell recordings from M 1 À/À mice have shown reduced or lack of both phasic and tonic cholinergic modulation of CA1 and CA3 pyramidal neurons, while M 3 À/À mice only displayed minor effects on tonic modulation (Dasari and Gulledge, 2011; Kremin et al., 2006) . In addition, neurons from M 4 À/À mice display a reduced suppression of Schaffer-collateral excitatory postsynaptic potentials (EPSPs) by the non-selective cholinergic receptor agonist carbachol (Dasari and Gulledge, 2011) . Thus, acetylcholine can modulate pyramidal neuron excitability directly as well as through alterations of synaptic transmission between CA3 and CA1 pyramidal neurons. In line with this, muscarinic-induced hippocampal gamma oscillations in CA3 neuron were absent in M 1 À/À mice but normal in M 2 -M 5 knockout lines, and carbachol-induced depression of transmission at excitatory synapses was blunted in M 4 À/À mice (Fisahn et al., 2002; Shirey et al., 2008) . At 6 months of age, M 5 À/À mice showed reduced spontaneous neuronal activity in CA3 pyramidal neurons, but this effect could be secondary to the severe cerebrovascular deficiency that becomes apparent in aging M 5 À/À mice (Araya et al., 2006) . Measured by in vivo microdialysis, data from mice lacking M 2 , M 3 , M 4 or a combination of those subtypes indicated that several mAChRs play a role in regulating hippocampal acetylcholine release, with the M 2 and M 3 receptors appearing to modulate cholinergic responses to environmental and pharmacological manipulations, although M 5 À/À mice and, importantly, M 1 À/À mice, were not examined (Tzavara et al., 2006 (Tzavara et al., , 2003 .
GABAergic hippocampal interneurons also modulate firing frequency, neuronal excitability, and membrane potential oscillations in a cell type dependent manner, through M 1 and M 3 receptors (Cea-del Rio la et al., 2010; . In addition, muscarinic attenuation or amplification of excitatory signals in interneurons occurs in a layer-specific fashion, which appears to depend critically on the differential expression of M 2 receptors (Zheng et al., 2011) , further indicating the level of complexity at which this region is regulated by mAChRs. Other hippocampal signaling systems are also modulated by mAChRs. In CA1 pyramidal neurons, cholinergic activation of extracellular signal-regulated kinase (ERK) 1/2 was shown to occur through stimulation of M 1 receptors, but not M 2 , M 3 , or M 4 receptors (Berkeley et al., 2001) . Similarly, mAChR agonist-induced activation of the mitogen-activated protein kinase (MAPK) pathway was virtually abolished, and phosphatidyl inositol (PI) hydrolysis was reduced, in cortical cultures from M 1 À/À mice . In hippocampal neuron cultures, postsynaptic M 1 and/or M 3 receptors were also found to mediate release of endocannabinoids from postsynaptic neurons and retrogradely suppress inhibitory synaptic transmission by activating presynaptic cannabinoid CB1 receptors (Fukudome et al., 2004; Ohno-Shosaku et al., 2003) . Most investigations have focused on selected subtypes, and it would be useful to compare phenotypes of all M 1 -M 5 knockout mice under identical experimental conditions in order to gain a fuller understanding of mAChR modulation of hippocampal functions.
Cortical and other brain functions
Similar to hippocampal pyramidal neuron, pyramidal neurons in the neocortex (layer 5) also respond to acetylcholine mainly via activation of M 1 receptors, and with only minor involvement of M 3 receptors (Gulledge et al., 2009) . M 2 or M 4 knockout lines were not tested. In both cortex and hippocampus, M 1 -mediated cholinergic transmission is suggested to be by volume transmission (Yamasaki et al., 2010) . In occipital slices of mouse visual cortex from M 1 -M 5 knockout lines, M 2 and M 4 receptor were demonstrated to facilitate synaptic transmission, while multiple mAChRs seem to mediate depression of synaptic transmission (Kuczewski et al., 2005 ; see section 2.2). Unlike in the hippocampus (Fisahn et al., 2002; Rouse et al., 2000) , muscarinic-agonist medicated inhibition of tonically active voltage dependent potassium channel (Mcurrent) was absent in sympathetic ganglion neurons of M 1 À/À mice (Hamilton et al., 1997) . This effect may be the basis for the lack of muscarinic agonist-induced seizures in M 1 À/À mice (see section 2.1). In addition, muscarinic agonist administration in the Bed nucleus of the stria terminalis produces long lasting reduction of stimulus evoked EPSP amplitude, an effect that has been attributed to M 2 receptors, although only M 1 À/À and M 2 À/À M 4 À/À lines were studied (Guo et al., 2012) .
Neuronal plasticity, LTD, and LTP
Acetylcholine also modulates neuronal plasticity through mAChRs in several brain regions. While studies using knockout mice indicate that several muscarinic receptors are important mediators of neuronal plasticity, their overall contributions remain unclear and appear dependent upon the brain region investigated. One reason for this may be that only selected lines were typically investigated for a given tissue/neuronal population. Systematic investigation of multiple receptors across tissues might reveal more cohesive functions of some subtypes, or might confirm a high level of cell type-dependent complexity.
Striatal MSNs show long-term potentiation (LTP) and longterm depression (LTD) in response to input patterns from glutamatergic afferents. Studies using striatal slices from mAChR knockout mice lacking M 2 and/or M 4 receptors indicate that M 2 and M 4 receptors predominantly play a role in the induction of LTD, and not LTP, probably via their autoreceptor function modulating cholinergic tone (Bonsi et al., 2008 (Bonsi et al., 2008) . LTD could be rescued using the M 1 receptor antagonist pirenzepine, or by depleting endogenous acetylcholine using hemicholinium-3, suggesting that the loss of LTD in the M 4 receptor-deficient mice was caused by increased cholinergic tone, and at least partly by the resulting increased stimulation of M 1 receptors (Bonsi et al., 2008) . Furthermore, pharmacological stimulation of M 4 receptors using the positive allosteric modulator (PAM) VU10010 induced LTD in D 1 -expressing directpathway MSN, which was abolished in D 1 -neuron-specific M 4 À/À mice (Shen et al., 2015) . While LTP itself appeared normal in mice lacking M 2 /M 4 receptors, LTP can be reverted to resting levels by low frequency stimulation (synaptic depotentiation), and this effect was abolished in corticostriatal slices from M 2 À/À M 4 À/À mice (Martella et al., 2009 ). Thus, in striatal tissue, M 2 /M 4 receptors appear necessary for the induction of LTD, and for inhibition/ modulation of LTP. However, in nucleus accumbens MSN, the mAChR agonist-induced increase in EPSC amplitude appears dependent upon M 5 receptors (Shin et al., 2015) . The above findings on striatal neuronal plasticity do not necessarily generalize to all brain regions. In mouse hippocampal slices, LTP measured in CA1 was decreased in M 2 À/À mice, LTPenhancement by the non-selective cholinergic receptor agonist carbachol was abolished, and short-term potentiation was abolished (Seeger et al., 2004) . In the CA3, M 2 À/À mice showed an inputspecific effect on LTP, suggesting that M 2 receptors promote LTP and short-term facilitation at associational/commissural fiber inputs and inhibit LTP at mossy fiber inputs with little effect on short-term plasticity (Zheng et al., 2012) . Thus, in hippocampal tissue, M 2 receptors appear important for the induction of LTP, consistent with M 2 À/À mice showing impairments in memory tasks.
For the predominantly post-synaptic subtypes M 1 and M 3 , knockout mouse studies suggest that, at least in the hippocampus, these receptors are involved not in the induction of LTD or LTP per se, but rather, modulate the degree of LTP or LTD in response to cholinergic stimulation (pharmacological or endogenous). LTP induction after electrical stimulation was intact in hippocampal slices from M 1 À/À mice, forebrain-specific M 1 À/À mice, and M 3 À/À mice (Kamsler et al., 2010; Shinoe, 2005) . However, while carbachol or electrically evoked acetylcholine release enhanced LTP in wildtype mice and in M 3 À/À mice, this effect was abolished in the M 1 À/ À mice (Anagnostaras et al., 2003; Shinoe, 2005) . A combination of pharmacological and knockout approaches demonstrated that M 1 receptor stimulation can increase glutamatergic synaptic transmission in CA1 pyramidal neurons, in a mechanism similar to electrically induced LTP (Dennis et al., 2016) . Similarly, studies in mice lacking M 1 receptors in specific brain tissues indicated that CA3 M 1 receptors are needed for presynaptic induction of glutamatergic LTD in hippocampus (Kamsler et al., 2010) . In addition to classic cell surface mAChR signaling, recent studies in cultured cortical and hippocampal neurons suggest that intracellular mAChRs, which experiments in knockout mice confirmed to be M 1 , can mediate enhancement of LTP through ERK 1/2 phosphorylation (Anisuzzaman et al., 2013) . Finally, both LTP measured at CA3 mossy fiber synapses and short-term plasticity (paired-pulse facilitation of field EPSPs) was decreased in M 5 À/À mice, although these effects may be a consequence of pronounced cerebrovascular deficiency that develops in aging M 5 À/À mice (Araya et al., 2006;  see section 2.3).
In visual cortex slices, low frequency stimulation caused a normal LTD in M 2 À/À M 4 À/À mice, but theta-burst stimulations failed to induce LTP in the M 2 À/À M 4 À/À mice (Origlia et al., 2006) . However, normal LTP in visual cortex slices from single receptor knockout M 2 À/À mice and M 4 À/À mice suggests a redundant function of both inhibitory autoreceptors in cortical LTP (Origlia et al., 2006) . In the same preparations, deletion of M 1 and/or M 3 receptors had no effect on LTP, but caused abnormal plasticity patterns after lowfrequency stimulation that elicited LTD in wild-type controls, including reversal from LTD to LTP (Origlia et al., 2006) . Thus, in cortex, LTP appears dependent upon M 2 /M 4 receptors, while LTD appears dependent upon M 1 /M 3 receptors (Origlia et al., 2006) . In the cerebellum, mAChR stimulation has suppressive effects on parallel fiber LTP, an effect that also appears to be mediated through M 1 and/or M 3 receptors (Rinaldo and Hansel, 2013 ).
Caveats and compensatory changes in knockout mice
A concern about the use of constitutive, whole-body knockout mice is the potential for unintended developmental or compensatory changes that may confound findings. In an attempt to uncover the most likely or obvious changes, studies using mAChR knockout mice have examined expression levels of the remaining mAChR subtypes, and of gene products in some other neurotransmitter systems. Surprisingly few changes were found. In M 1 À/À mice, studies reported normal expression levels of M 2 -M 5 subtypes and dopamine receptors in all brain regions that were examined (Fisahn et al., 2002; Gerber et al., 2001; Hamilton et al., 1997; Miyakawa et al., 2001) . Similarly in M 2 À/À and M 4 À/À mice, no changes in brain mAChR or dopamine receptor levels were reported (Gomeza et al., 1999a (Gomeza et al., , 1999b Karasawa et al., 2003; Schmidt et al., 2011; Zhang et al., 2002a) , and even deletion of both M 2 and M 4 subtypes did not lead to changes in M 1 or M 3 subtype levels (M 5 levels were not measured; Duttaroy et al., 2002) . at the University of Toronto (Yeomans group), which could account for some apparent discrepancies between findings obtained in the two strains (Wang et al., 2004) . It is possible that changes in receptor levels in specific cell types or smaller brain regions went undetected when measuring levels at the brain region level. For instance, knockout of the M 2 or M 3 subtype led to measurable expression of M 1 receptors in isolated cochlea, where the receptor was not detected in wild-type mice, and M 1 À/À mice and M 3 À/À mice showed elevated levels of M 2 receptors in the cochlea (Maison et al., 2010) . Nevertheless, it seems unlikely that compensatory changes accounted for major findings using mAChR knockout mice. As the use of tissue-specific knockout approached become more common, the development of compensatory changes may become less of a concern (see section 3, and Wess, 2012)).
Specific CNS functions, disease states, and drug target potential
Beyond basic research into neuronal functions, mAChR knockout mice also continue to provide insights into specific CNS functions and disease states. The medications development potential for mAChRs gained renewed attention in the past decade with the emergence of (long elusive) ligands with high subtype selectivity (Nickols and Conn, 2014) . CNS conditions for which muscarinic approaches are being investigated include Alzheimer's disease, schizophrenia, substance abuse, and Parkinson's disease (reviewed in Davie et al., 2013; Dencker et al., 2012a; Foster et al., 2014a; Kruse et al., 2014; Raffa, 2009; Wess, 2012 Wess, , 2004 Wess, , 2003 Wess et al., 2007) .
Autonomic nervous system
Muscarinic receptors mediate a wide range of functions of the parasympathetic nervous system, centrally and peripherally, and these effects were some of the first to be investigated using mAChR knockout mice. This section provides a brief overview of CNS-related effects only. Basal body temperature is slightly decreased in M 1 À/À mice and M 3 À/À mice, and studies indicated that temperature regulation, either by infection or mAChR agonist-induced, is mediated through M 2 and M 3 receptors, and likely not M 1 /M 4 /M 5 receptors (Boudinot et al., 2004; Bymaster et al., 2003; Gomeza et al., 1999a Gomeza et al., , 1999b Turner et al., 2010; Yamada et al., 2001 ). Sleep patterns, including slow-wave and REM sleep, were recorded in M 2 À/À mice and M 4 À/À mice, and were normal at baseline, although M 2 À/À mice showed altered patterns after sleepdisturbing manipulations (Turner et al., 2010) . The amount of paradoxical sleep was also normal in mice lacking both M 2 and M 4 receptors, but was reduced in M 3 À/À mice (Goutagny et al., 2005) .
However, analysis of theta wave electroencephalogram activity revealed altered patterns in both M 3 À/À mice and M 2 À/À M 4 À/À double knockout mice (Goutagny et al., 2005 Hamilton et al., 1997; Takeuchi et al., 2002) . M 1 receptors do not appear to play a role in induction of seizures by kainic acid or organophosphates (Hamilton et al., 1997; Kow et al., 2014 ; see also section 2.7 for HPA axis modulation).
Sensory systems and nociception
Deletion of one or more of the M 1 -M 4 receptors led to moderate alterations in the organization, neuronal connectivity, and/or synaptic transmission in the visual cortex, which could predict altered peripheral vision and precision of visual perception, although no gross deficits in visual acuity were detected in any strain (Groleau et al., 2014; Kuczewski et al., 2005) . Indeed M 1 À/À mice and M 4 À/À mice performed normally in a task requiring visual discrimination of similar, complex images (Bartko et al., 2011; Bubser et al., 2014; Gould et al., 2015) . M 2 /M 4 , but not M 1 /M 3 /M 5 receptors, appear to play a role in cochlear function and auditory processing (Maison et al., 2010) . Despite normal hearing, M 1 À/À mice performed poorly in an auditory-cued task but normally in similar, visuallycued tasks, consistent with the abnormal cortical processing of auditory information in M 1 À/À mice (Miyakawa et al., 2001; Zhang et al., 2006 Zhang et al., , 2005 . Stimulation of mAChRs can produce strong analgesic effects, both at the peripheral, spinal, and brain level. Analgesic effects of the non-subtype-selective mAChR agonist oxotremorine in tail flick and hot plate tests were reduced in M 2 À/À mice, largely normal in M 4 À/À mice, but completely lacking in mice lacking both M 2 and M 4 receptors, while effects of morphine were preserved Gomeza et al., 1999a Gomeza et al., , 1999b . This is consistent with the functions of M 2 and M 4 receptors at the spinal level, primarily inhibiting pain transmission, while M 3 and M 5 receptors may provide subtler, more complex modulation of nociception (Chen and Pan, 2005; Chen et al., 2014 Chen et al., , 2010 Zhang et al., 2007) . Some of the analgesic effects of systemically administered mAChR agonists may also be due to stimulation of M 2 receptors on peripheral nerves (Bernardini et al., 2002; De Angelis et al., 2014) . M 1 À/À mice had normal baseline pain responses in the hot plate test but showed increased potency of morphine (Carrigan and Dykstra, 2007; Miyakawa et al., 2001) . Together, those studies suggest a potential for M 2 agonists as analgesics, see also Wess et al., 2003 for review).
Cognitive function, memory, and Alzheimer's disease
As described in section 1.2, multiple mAChRs are implicated in LTP and LTD, which are essential for learning and memory functions. These functions are confirmed at the behavioral level by specific alterations in cognitive performance in knockout mice. Pharmacological and knockout studies converge to support the role of M 1 receptors in memory consolidation, as well as in a "top down" processing (i.e., goal-oriented or rule-based processing, as opposed to "bottom-up", sensory-driven processing) and nonmatching-to-sample tasks (Anagnostaras et al., 2003; Bartko et al., 2011; Gould et al., 2015; Young and Thomas, 2014) . M 1 À/À mice, despite being generally hyperactive, show normal or improved performance in attentional function, matching-tosample tasks, spatial reference, and reversal (Anagnostaras et al., 2003; Bartko et al., 2011; Miyakawa et al., 2001 ). Thus, M 1 receptors appear important for cortex-dependent processing and cortex-hippocampus interaction rather than hippocampusdependent memory per se. M 2 À/À mice have shown deficits in various cognitive domains including working memory, spatial learning, and behavioral flexibility, although performance sometimes normalized to wild-type level with more training (Bainbridge et al., 2008; Seeger et al., 2004; Tzavara et al., 2003) . Loss of M 3 receptor signaling through a G protein-independent, phosphorylation-arrestin-dependent pathway decreased fear conditioning (Poulin et al., 2010) , suggesting a use for second messenger pathway-biased allosteric M 3 receptor ligands. M 4 À/À mice showed normal spatial reference, visual discrimination, working and episodic-like memory, but were delayed in acquiring discrimination of an interoceptive (drug) cue and showed pronounced deficits in fear conditioning (Bubser et al., 2014; Koshimizu et al., 2012; Thomsen et al., 2012; Tzavara et al., 2003) . Degeneration of cholinergic neurons projecting to cortical and hippocampal areas is central to the pathophysiology of Alzheimer's disease, the most common dementia, and M 1 agonists show promise in reducing b-amyloid plaques and neurofibrillary tangles, and in restoring cognitive function (Davie et al., 2013) . In transgenic mice with amyloid precursor or tau protein mutations, used as models of Alzheimer's disease, knockout of M 1 receptors dramatically exacerbated b-amyloid and plaque formation, inflammation, tau pathology, and cognitive deficits Medeiros et al., 2011) . Impaired cerebrovascular function may also contribute to cognitive symptoms in Alzheimer's disease and focal cerebral ischemia. M 5 À/À mice lack acetylcholine-induced arterial blood vessel dilation in the brain (but not peripherally), and male M 5 À/À mice 6 months or older showed reduced cerebral blood flow, neuronal atrophy and astrocyte swelling in cortex and hippocampus, and deficits in spatial and non-spatial memory, which were corrected by estrogen (Araya et al., 2006; Kitamura et al., 2009; Yamada et al., 2001 ).
Schizophrenia and psychosis
Muscarinic receptor agonists have received much interest as potential targets in the treatment of schizophrenia, not only for antipsychotic actions, but also for ameliorating cognitive symptoms (Carruthers et al., 2015; Felder et al., 2001 ; see section 2.3). Mice lacking M 1 or M 4 receptors have phenotypes reminiscent of schizophrenia symptoms, including modest sensory gating deficits that were compounded to significant deficits in female mice lacking both receptors, as measured by prepulse inhibition (PPI) of the startle reflex (Koshimizu et al., 2012; Thomsen et al., 2010b) . M 4 À/À mice showed altered social behaviors, such as briefer contacts with other mice (Koshimizu et al., 2012) . At least one line of M 5 À/À mice also showed PPI deficits (Thomsen et al., 2007 , but see Wang et al., 2004) . The moderately M 1 /M 4 -selective agonist xanomeline showed some promise in clinical trials, but side effects due to off-target affinity limited its clinical usefulness. Knockout studies have helped elucidate the mechanism of action of mAChR agonists, paving the way for more targeted approaches using selective ligands. In preclinical assays predictive of antipsychotic effects, xanomeline and the M 1 /M 2 /M 4 agonist BuTAC were effective in wild-type mice, M 1 À/À mice, and/or M 2 À/À mice, but effects were absent or reduced in mice lacking M 4 receptors, indicating that M 4 receptor stimulation is essential to produce antipsychotic effects Thomsen et al., 2010b; Woolley et al., 2009 ; see also section 3). Possible antipsychotic effects at other subtypes cannot be excluded, because the non subtype-selective agonist oxotremorine still reversed muscarinic antagonist-induced PPIdeficits in mice lacking M 1 , M 4 , or both receptors (Thomsen et al., 2010b) . Antipsychotic-like effects of typical and atypical antipsychotics ( Thomsen et al., 2010b Thomsen et al., , 2007 Watt et al., 2013) . The involvement of non-M 4 subtypes in cataleptogenic effects have not been tested. The above findings support the potential usefulness of mAChR ligands in the treatment of schizophrenia and psychotic disorders, in particular M 4 agonists as antipsychotics, and M 1 agonists as cognitive enhancers.
Addiction
M 1 and M 4 receptors are richly expressed in striatal tissues including the nucleus accumbens, and modulate striatal dopamine signaling, including in response to drugs of abuse. M 1 À/À mice, and to a lesser extent M 4 À/À mice, are hyperdopaminergic, hyperactive, and hypersensitive to psychomotor stimulants and dopamine agonists Gerber et al., 2001; Gomeza et al., 1999b; Guo et al., 2010a; Jeon et al., 2010; Miyakawa et al., 2001; Tzavara, 2004) . Conversely, M 4 À/À mice have shown decreased sensitivity to dopamine antagonists Thomsen and Caine, 2016) . M 4 À/À mice also self-administered more cocaine and alcohol than wild-type controls, although effects may extend to non-drug reinforcers (de la Cour et al., 2015; Schmidt et al., 2011) . Perhaps surprisingly, M 1 À/À mice showed decreased conditioned place preference to cocaine and morphine, although effects on memory could explain these findings (Carrigan and Dykstra, 2007) . The above findings suggest that M 1 and M 4 agonists may be of use in the treatment of drug addictions. Indeed, a combination of knockout and pharmacological approaches showed that stimulating either M 1 or M 4 receptors can attenuate effects of cocaine, including in drug self-administration (Dencker et al., 2012b; Thomsen et al., 2012 Thomsen et al., , 2010a . M 5 receptors are uniquely located in the dopaminergic reward pathway, and knockout studies revealed their role in modulating striatal dopamine (Bendor et al., 2010; Forster et al., 2002; Foster et al., 2014b; Garz on and Pickel, 2013; Wasserman et al., 2013; Yamada et al., 2001) . Behavioral and molecular effects of both opioids and cocaine are attenuated in M 5 À/À mice (two independently generated mouse lines), including in self-administration paradigms Fink-Jensen et al., 2003; Steidl et al., 2011; Steidl and Yeomans, 2009; Thomsen et al., 2005) . However, at least some effects of monoamine releasers like Damphetamine, contrary to the monoamine reuptake inhibitor cocaine, appear increased in M 5 À/À mice (Schmidt et al., 2010 ; but 
Parkinson's disease
Extrapyramidal control of movement is dependent upon balanced activities of muscarinic cholinergic and dopaminergic systems, loss of this balance being a hallmark of Parkinson's disease. The non subtype-selective mAChR agonist oxotremorine induces tremor, akinesia, and tremulous jaw movements that are all reversible by the anti-Parkinson treatments including L-DOPA, and are therefore used as preclinical assays in Parkinson research. Oxotremorine-induced tremor appears to be mediated entirely through M 2 receptors (i.e., normal response in mice lacking M 1 , M 3 , M 4 , or M 5 receptors), and, remarkably, was abolished in both M 2 À/À mice and in heterozygous M 2 þ/À mice Gomeza et al., 1999a Gomeza et al., , 1999b . The cataleptogenic effects of antipsychotic drugs were attenuated in M 4 À/À mice, as were (moderately) oxotremorine-induced tremulous jaw movements (FinkJensen et al., 2011; Salamone et al., 2001 ; but see Karasawa et al., 2003) . The incomplete loss of effect and the preserved anti-cataleptogenic effects of the mAChR antagonist scopolamine in the M 4 À/ À mice indicates that other subtypes are involved as well (FinkJensen et al., 2011) . Blockade of striatal M 1 and M 4 mAChRs improved motor deficits in the 6-hydroxydopamine lesion model (Ztaou et al., 2016) . The usefulness of mAChR ligands may be complicated by the delicate balancing of improving motor function (mAChR antagonist approach) and cognitive function (mAChR agonist approach).
Anxiety and depression
M 4 À/À mice showed decreased anxiety-like behaviors in a shockprobe burying test (Degroot and Nomikos, 2006) , while M 1
À/À mice, and M 5 À/À mice performed comparably to wild-type controls in the light-dark transition test and/or elevated plus-maze (Fink-Jensen et al., 2003; Miyakawa et al., 2001; Poulin et al., 2010; Seeger et al., 2004) . Central, muscarinic modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis, including corticosterone release, appears mediated through multiple receptors including M 1 , M 3 , and M 4 receptors, with some seemingly conflicting results in M 2 À/À mice e perhaps due to compensatory mechanisms (Gautam et al., 2009; Hemrick-Luecke et al., 2002; Rhodes et al., 2008 Rhodes et al., , 2005 . Muscarinic receptor antagonists may also provide a new approach to fast-acting antidepressant medication, with pharmacological and knockout studies converging on M 1 and M 2 receptors as the targets (Witkin et al., 2014) .
Tissue-selective knockouts
Mice lacking a given mAChR selectively in the CNS (neurons and glial cells) can be generated by crossing floxed mAChR strains with Nestin-Cre transgenic mice. This approach uncovered surprising functions of CNS M 3 receptors: growth hormone production, as well as promotion of bone formation and inhibition of bone resorption via decreased sympathetic tone (Gautam et al., 2009; Shi et al., 2010) .
Others have used the Cre-Lox approach to generate mice lacking a given receptor only in specific cell types. Foster et al., 2016; Ztaou et al., 2016) . In contrast, "cocaine-blocking" effects of M 4 receptor stimulation were only attenuated in the D 1 -M 4 À/À mice, indicating that M 4 receptors on other cell types also participate in this effect (Dencker et al., 2012b) . Finally, electrophysiological experiments in these mice showed that M 4 receptors located on the D 1 -expressing MSN are necessary for the development of LTD of corticostriatal glutamatergic synapses by endogenous acetylcholine signaling (Shen et al., 2015) . By a similar approach, mice lacking M 1 receptors in selected tissues have been generated: forebrain specific (FB-M 1 À/À ), and further restricted to the hippocampal CA3 pyramidal neurons, or parvalbumin-containing GABAergic interneurons (PV-M 1 À/À ). Unlike whole-body M 1 À/À mice, the FB-M 1 À/À mice and PV-M 1 À/À mice were not hyperactive, in agreement with the notion that the hyperactivity stems from effects in striatal tissues (Kamsler et al., 2010; Yi et al., 2014) . CA3 M 1 receptors were found to be necessary for presynaptic induction of glutamatergic LTD, while PV M 1 receptors appear to play a role in PV interneuron excitability, learning/memory and mAChR agonist-induced seizures (Kamsler et al., 2010; Yi et al., 2014) .
Conclusions
Knockout mice have proved an invaluable tool in elucidating physiological functions of CNS mAChRs. Studies using knockout mice helped demonstrate how acetylcholine from local interneurons and projection neurons provides powerful and complex modulation of neuronal activity and plasticity via different mAChR subtypes, in brain regions such as the striatum, hippocampus, and neocortex. Phenotypic analysis of mAChR knockout mice revealed deficits or changes in CNS functions ranging from basic autonomic functions like body temperature regulation and sleep, over motor and sensory systems, to complex cognitive functions. Combined with recently developed allosteric subtype-selective agonists, antagonists, and modulators, knockout mouse experiments have uncovered promising new medications development possibilities, which indicate that mAChR ligands may be of use in the treatment of pain, Alzheimer's disease and other memory/cognitive impairment, schizophrenia, addiction, depression, and more.
